Crucell N.V.
AMS:CRXL ISIN:NL0000358562
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
News
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands, 21 October 2008 - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that an agreement was reached to relocate Crucell's Korean production facility, where its pentavalent children's vaccine Quinvaxem® and a hepatitis B vaccine Hepavax-Gene® are produced, from the Shingal site in Yongin City, Korea to the Incheon Free Economic Zone.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands/Paris, France, 17 October 2008 - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) and the Aeras Global TB Vaccine Foundation today announce the start of a Phase I clinical trial in Kenya of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35. The announcement is made in the lead up to the 39th Union World Conference on Tuberculosis and Lung Disease in Paris, France (16-20 October, 2008).
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (October 3, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it received a National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) contract aimed at advancing the development of a multivalent filovirus vaccine that includes both Ebola and Marburg viruses. The contract provides funding of up to $30 million, with additional options that may be triggered at the discretion of the NIH worth a further $40 million.
Crucell N.V. (AMS:CRXL) Additional Milestone Achieved in Collaboration Agreement with sanofi pasteur
Crucell N.V. (AMS:CRXL) Groningen/Leiden, The Netherlands; Parsippany, USA, 29 September 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that the high-titer fed-batch process developed at the PERCIVIA PER.C6® Development Center, their joint venture in Cambridge, USA was recently scaled up to 250 liters by DSM Biologics scientists at their GMP facility in Groningen, The Netherlands. They successfully achieved 8 grams per liter for an IgG expressed by PER.C6® cells using chemically defined cell culture medium in a SUB (single-use bioreactor).
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (September 26, 2008) - For several years the vaccine producer Berna Biotech a Swiss affiliate of Crucell N.V. has been working rigorously on the 3R program, which has a goal to Reduce, Refine and Replace all animal testing. The development of in-vitro alternatives as well as the strategic imperative of Berna Biotech to eliminate animal testing has resulted in the company announcing, that it will cease all animal testing and therefore close the animal house in Bern in 2008. Crucell's Swiss affiliate Berna Biotech whose goal is to fight infectious diseases and save lives by bringing innovation to global health has reached another important milestone in the production of modern vaccines.
Crucell N.V. (AMS:CRXL) Basel, Switzerland / Leiden, The Netherlands (September 25, 2008) - Lonza (Swiss Exchange: LONN) and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) entered into a co-exclusive manufacturing, sales and distribution agreement related to the PERMEXCIS(TM) cell culture medium developed by Crucell for PER.C6® cells. Under this agreement, Lonza will manufacture the medium, and in addition will market and sell it on a global basis. Financial details of the agreement were not disclosed.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (September 23, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that supranational organizations awarded Crucell new contracts of $140 million for supplies of Quinvaxem® and Hepavax-Gene® for the period 2008 - 2009, bringing the total for the period 2007 - 2009 to $0.5 billion.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (September 18, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it has signed an exclusive, commercial license agreement with North Carolina-based Talecris Biotherapeutics for an undisclosed and specific protein to be produced using the PER.C6® cell line.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (August 26, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it intends to move Dukoral® and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites within the Crucell organization, resulting in additional cost savings beyond 2011.
###
3,609 COMPANY PROFILE VIEWS
- Diese Seite wurde besucht: (letzten 7 Tagen: 11) (letzten 30 Tagen: 60) (seit Veröffentlichung: 3588)
